Tissue-Free vs Tumor-Informed ctDNA Assays for Molecular Residual Disease Detection in Early Triple Negative Breast Cancer
A simpler blood test for cancer recurrence risk works as well as tumor-specific tests, potentially opening faster treatment decisions for triple-negative breast cancer patients.
A multicenter prospective cohort study of 159 TNBC patients compared tissue-free cancer-differential methylation ctDNA against tumor-informed dPCR for molecular residual disease detection, finding tissue-free detected MRD in 34% with HR 27.2 for recurrence and a 7.9-month lead time. This first head-to-head comparison demonstrates tissue-free ctDNA performance is comparable to tumor-informed assays, directly addressing a key workflow barrier to MRD-guided adjuvant therapy decisions.
What the study was
- Study design
- multicenter_prospective_cohort
- Population
- Triple negative breast cancer patients in post-treatment MRD surveillance
- Sample size
- 159
- Category
- Early Detection
- Maturity
- Validated
- Journal
- JAMA Oncology
Why it surfaced
JAMA Oncol, prospective multicenter, n=159; first head-to-head comparison of tissue-free vs tumor-informed ctDNA in TNBC post-treatment surveillance; directly addresses workflow barrier to MRD-guided adjuvant therapy decisions
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.